Repeated versus single praziquantel dosing regimen in treatment of female genital schistosomiasis: a phase 2 randomised controlled trial showing no difference in efficacy

Repeated versus single praziquantel dosing regimen in treatment of female genital schistosomiasis: a phase 2 randomised controlled trial showing no difference in efficacy

BackgroundSingle-dose praziquantel (PZQ) for treating urogenital schistosomiasis has been reported as inadequate for achieving significant resolution of female genital schistosomiasis (FGS)-associated cervicovaginal lesions. This randomised controlled trial aimed to assess the efficacy and safety of...

Full description

Bibliographic Details
Main Authors: Louise Thomsen Schmidt Arenholt, Bodo Sahondra Randrianasolo, Tiana Onintsoa Oliva Rabozakandraina, Charles Emile Ramarokoto, Karoline Jøker, Katrina Kæstel Aarøe, Dorthe Brønnum, Caspar Bundgaard Nielsen, Suzette Sørensen, Mads Lumholdt, Martin Jensen, Søren Lundbye-Christensen, Jørgen Skov Jensen, Paul Corstjens, Pytsje Hoekstra, Govert J van Dam, Noriko Kobayashi, Shinjiro Hamano, Peter Derek Christian Leutscher
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-08-01
Series:Frontiers in Tropical Diseases
Subjects:
Schistosoma haematobium
female genital schistosomiasis
praziquantel
urogenital complaints
gynaecological manifestations
Online Access:https://www.frontiersin.org/articles/10.3389/fitd.2024.1322652/full

Internet

https://www.frontiersin.org/articles/10.3389/fitd.2024.1322652/full

Similar Items